Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1995 Dec 19;92(26):12270–12274. doi: 10.1073/pnas.92.26.12270

Differential recognition of the type I interferon receptor by interferons tau and alpha is responsible for their disparate cytotoxicities.

P S Subramaniam 1, S A Khan 1, C H Pontzer 1, H M Johnson 1
PMCID: PMC40338  PMID: 8618883

Abstract

Interferon tau (IFN tau), originally identified as a pregnancy recognition hormone, is a type I interferon that is related to the various IFN alpha species (IFN alpha s). Ovine IFN tau has antiviral activity similar to that of human IFN alpha A on the Madin-Darby bovine kidney (MDBK) cell line and is equally effective in inhibiting cell proliferation. In this study, IFN tau was found to differ from IFN alpha A in that is was > 30-fold less toxic to MDBK cells at high concentrations. Excess IFN tau did not block the cytotoxicity of IFN alpha A on MDBK cells, suggesting that these two type I IFNs recognize the type I IFN receptor differently on these cells. In direct binding studies, 125I-IFN tau had a Kd of 3.90 x 10(-10) M for receptor on MDBK cells, whereas that of 125I-IFN alpha A was 4.45 x 10(-11) M. Consistent with the higher binding affinity, IFN alpha A was severalfold more effective than IFN tau in competitive binding against 125I-IFN tau to receptor on MDBK cells. Paradoxically, the two IFNs had similar specific antiviral activities on MDBK cells. However, maximal IFN antiviral activity required only fractional occupancy of receptors, whereas toxicity was associated with maximal receptor occupancy. Hence, IFN alpha A, with the higher binding affinity, was more toxic than IFN tau. The IFNs were similar in inducing the specific phosphorylation of the type I receptor-associated tyrosine kinase Tyk2, and the transcription factors Stat1 alpha and Stat2, suggesting that phosphorylation of these signal transduction proteins is not involved in the cellular toxicity associated with type I IFNs. Experiments using synthetic peptides suggest that differences in the interaction at the N terminal of IFN tau and IFN alpha with the type I receptor complex contribute significantly to differences in high-affinity equilibrium binding of these molecules. It is postulated that such a differential recognition of the receptor is responsible for the similar antiviral but different cytotoxic effects of these IFNs. Moreover, these data imply that receptors are "spare'' with respect to certain biological properties, and we speculate that IFNs may induce a concentration-dependent selective association of receptor subunits.

Full text

PDF
12270

Images in this article

12273Fig. 5
on p.12273
12273Fig. 7
on p.12273
12273Fig. 8
on p.12273

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aguet M., Mogensen K. E. Interferon receptors. Interferon. 1983;5:1–22. [PubMed] [Google Scholar]
  2. Armstrong J. A. Cytopathic effect inhibition assay for interferon: microculture plate assay. Methods Enzymol. 1981;78(Pt A):381–387. doi: 10.1016/0076-6879(81)78145-x. [DOI] [PubMed] [Google Scholar]
  3. Cleary C. M., Donnelly R. J., Soh J., Mariano T. M., Pestka S. Knockout and reconstitution of a functional human type I interferon receptor complex. J Biol Chem. 1994 Jul 22;269(29):18747–18749. [PubMed] [Google Scholar]
  4. Jarpe M. A., Johnson H. M., Bazer F. W., Ott T. L., Curto E. V., Krishna N. R., Pontzer C. H. Predicted structural motif of IFN tau. Protein Eng. 1994 Jul;7(7):863–867. doi: 10.1093/protein/7.7.863. [DOI] [PubMed] [Google Scholar]
  5. Langer J. A., Pestka S. Procedures for studying binding of interferon to human cells in suspension cultures. Methods Enzymol. 1986;119:305–311. doi: 10.1016/0076-6879(86)19046-x. [DOI] [PubMed] [Google Scholar]
  6. Li J., Roberts R. M. Interferon-tau and interferon-alpha interact with the same receptors in bovine endometrium. Use of a readily iodinatable form of recombinant interferon-tau for binding studies. J Biol Chem. 1994 May 6;269(18):13544–13550. [PubMed] [Google Scholar]
  7. Lopez A. F., Elliott M. J., Woodcock J., Vadas M. A. GM-CSF, IL-3 and IL-5: cross-competition on human haemopoietic cells. Immunol Today. 1992 Dec;13(12):495–500. doi: 10.1016/0167-5699(92)90025-3. [DOI] [PubMed] [Google Scholar]
  8. McPherson G. A. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J Pharmacol Methods. 1985 Nov;14(3):213–228. doi: 10.1016/0160-5402(85)90034-8. [DOI] [PubMed] [Google Scholar]
  9. Mirando M. A., Short E. C., Jr, Geisert R. D., Vallet J. L., Bazer F. W. Stimulation of 2',5'-oligoadenylate synthetase activity in sheep endometrium during pregnancy, by intrauterine infusion of ovine trophoblast protein-1, and by intramuscular administration of recombinant bovine interferon-alpha I1. J Reprod Fertil. 1991 Nov;93(2):599–607. doi: 10.1530/jrf.0.0930599. [DOI] [PubMed] [Google Scholar]
  10. Pontzer C. H., Bazer F. W., Johnson H. M. Antiproliferative activity of a pregnancy recognition hormone, ovine trophoblast protein-1. Cancer Res. 1991 Oct 1;51(19):5304–5307. [PubMed] [Google Scholar]
  11. Pontzer C. H., Ott T. L., Bazer F. W., Johnson H. M. Localization of an antiviral site on the pregnancy recognition hormone, ovine trophoblast protein 1. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5945–5949. doi: 10.1073/pnas.87.15.5945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pontzer C. H., Ott T. L., Bazer F. W., Johnson H. M. Structure/function studies with interferon tau: evidence for multiple active sites. J Interferon Res. 1994 Jun;14(3):133–141. doi: 10.1089/jir.1994.14.133. [DOI] [PubMed] [Google Scholar]
  13. Pontzer C. H., Torres B. A., Vallet J. L., Bazer F. W., Johnson H. M. Antiviral activity of the pregnancy recognition hormone ovine trophoblast protein-1. Biochem Biophys Res Commun. 1988 Apr 29;152(2):801–807. doi: 10.1016/s0006-291x(88)80109-8. [DOI] [PubMed] [Google Scholar]
  14. Roberts R. M., Cross J. C., Leaman D. W. Interferons as hormones of pregnancy. Endocr Rev. 1992 Aug;13(3):432–452. doi: 10.1210/edrv-13-3-432. [DOI] [PubMed] [Google Scholar]
  15. Rubinstein M., Orchansky P. The interferon receptors. CRC Crit Rev Biochem. 1986;21(3):249–275. doi: 10.3109/10409238609113613. [DOI] [PubMed] [Google Scholar]
  16. Soos J. M., Subramaniam P. S., Hobeika A. C., Schiffenbauer J., Johnson H. M. The IFN pregnancy recognition hormone IFN-tau blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. J Immunol. 1995 Sep 1;155(5):2747–2753. [PubMed] [Google Scholar]
  17. Uzé G., Lutfalla G., Mogensen K. E. Alpha and beta interferons and their receptor and their friends and relations. J Interferon Cytokine Res. 1995 Jan;15(1):3–26. doi: 10.1089/jir.1995.15.3. [DOI] [PubMed] [Google Scholar]
  18. Whaley A. E., Meka C. S., Harbison L. A., Hunt J. S., Imakawa K. Identification and cellular localization of unique interferon mRNA from human placenta. J Biol Chem. 1994 Apr 8;269(14):10864–10868. [PubMed] [Google Scholar]
  19. Zoon K. C., Zur Nedden D., Arnheiter H. Procedures for studying the binding of interferon to human and bovine cells in monolayer culture. Methods Enzymol. 1986;119:312–315. doi: 10.1016/0076-6879(86)19047-1. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES